Skip to content
    Fairmount Funds logo

    Fairmount Funds

    West Conshohocken, United StatesFounded 2016
    fairmount.comLinkedIn
    Biotech & Life SciencesHealthcare

    Fairmount Funds Management is a registered investment adviser and healthcare-focused hedge fund based in West Conshohocken, Pennsylvania. The firm executes strategic equity investments across public and private biotechnology markets, targeting companies developing differentiated therapeutics.

    56% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Average disclosed round size is $186.3M (across 24 rounds with reported amounts).

    Find people at Fairmount Funds on Goldilocks AI

    Portfolio

    20

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    2

    Team

    NM

    Neal McCarthy

    Founding Partner and Managing Director

    AB

    Andrew Brown

    Managing Director

    AT

    Andrew T. Greenberg

    Managing Director

    CR

    Charles Robins

    Managing Director

    JS

    Jonathan Smith

    Managing Director - Investment Banking

    MP

    Michelle Pernice

    Operating Partner

    BF

    Bill Frame

    Director

    CC

    Chris Cain

    Director of Research

    JS

    JP Solomon

    Vice President

    PH

    Peter Harwin

    Managing Member

    TK

    Tomas Kiselak

    Managing Member

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    27 investments
    CompanyRoundAmountDate
    Mirador logoMiradorSeries B$250MJan 2026
    Mirador Tx logoMirador TxSeries B$250MJan 2026
    AAvere TherapeuticsUnknown$320MJan 2026
    AAvery TherapeuticsUnknown$69MJan 2026
    Crescent Biopharma logoCrescent BiopharmaGrowth$200MJun 2025
    Damora Therapeutics logoDamora TherapeuticsUnknown$284.9MJan 2025
    MMirador TherapeuticsUnknown$250MJan 2025
    Mirador Tx logoMirador TxSeries B$250MJan 2025
    Zenas BioPharma logoZenas BioPharmaSeries C$200MMay 2024
    Mirador Tx logoMirador TxUnknown$400MMar 2024
    Zenas BioPharma logoZenas BioPharmaSeries C$200MJan 2024
    Korsana Biosciences logoKorsana BiosciencesSeed$25MJan 2024
    BBicaraSeries C$165MDec 2023
    Bicara Therapeutics logoBicara TherapeuticsSeries C$165MDec 2023
    Apogee logoApogeeSeries B$149MDec 2022
    Apogee Therapeutics logoApogee TherapeuticsSeries A—Dec 2022
    Apogee Therapeutics logoApogee TherapeuticsSeries B$149MDec 2022
    EEnlivenSeed—Oct 2022
    Interius BioTherapeutics logoInterius BioTherapeuticsSeries A$76MMay 2021
    Nuvalent logoNuvalentSeries B$135MMay 2021
    EnLiven Therapeutics logoEnLiven TherapeuticsSeries B$85MDec 2020
    VVerona Pharma PLCUnknown$200MJan 2020
    EEnlivenSeries A$55MJan 2020
    Oruka Therapeutics logoOruka TherapeuticsGrowth$275M—
    SSensei BioUnknown$200M—
    Page 1 of 2

    Top Co-Investors

    Venrock Healthcare Capital Partners18 shared
    Logos Capital12 shared
    OrbiMed11 shared
    Wellington Management10 shared
    Fidelity Management & Research Company9 shared
    RA Capital Management6 shared
    Commodore Capital5 shared
    Perceptive Advisors5 shared
    Vivo Capital5 shared
    Rock Springs Capital5 shared
    Blue Owl Healthcare Opportunities5 shared
    Farallon Capital Management5 shared
    Boxer Capital5 shared
    Moore Strategic Ventures5 shared
    ARCH Venture Partners5 shared
    The Invus Group, LLC5 shared
    RTW Investments, LP4 shared
    Deep Track Capital4 shared
    Braidwell LP4 shared
    Quan Funds4 shared

    Last updated: 20 October 2026